OPINION
WHEN TRENDS TRAVEL FASTER THAN GOVERNANCE
From glass skin to treatment stacking, South Korea is shaping patient expectations. But does faster adoption mean better practice? Jen Vittanuova explores what UK aesthetics can learn, and why clinical judgement must keep pace with innovation.
South Korea’s influence on aesthetics offers plenty to learn from, but popularity should never replace clinical judgement. One practitioner considers where innovation ends and the need for greater scrutiny begins.
I keep seeing people say South Korea is ten years ahead of us in aesthetics. I don’t know if I’d go that far. Being quicker to adopt something doesn’t necessarily mean being clinically ahead, but there’s no denying its influence on what we’re doing, what patients are asking for and what we’re seeing on social media.
Korean skincare has become familiar on the UK high street. Then came glass skin, which seems to have gone from a Korean beauty ideal to something patients everywhere want to achieve. I understand the appeal. I like that we’ve moved some of the conversation away from filling lines and towards improving the skin itself.
Where I become cautious is when healthy skin becomes an expectation of completely smooth, poreless, reflective skin. Real skin has pores, texture, movement and variation. If a patient brings in an image shaped by treatments, make-up, lighting and filters as their expected outcome, there’s plenty to unpick before we discuss treatment.
WHEN A TREND BECOMES A TREATMENT REQUEST
The treatments are travelling just as quickly as the beauty ideals. Microtox, liquid microneedling and increasingly complicated combinations of devices, injectables and skin treatments are attracting attention.
Social media loves this because “I had ten treatments in one day in Korea” is considerably more interesting content than “I had a consultation, we decided I didn’t need half of these things and we’re going to review my skin in three months”.
That’s probably where my nurse brain starts fighting with my aesthetics brain.
I’m interested in new treatments. I wouldn’t still be working in aesthetics after all these years if I wasn’t. Being evidence-based doesn’t mean refusing to do anything until there are 20 years of data behind it. But we need to ask whether we’re adopting something because there’s a reasonable clinical rationale, or because patients are asking and everyone else appears to offer it.
Microtox illustrates the need for critical appraisal. A 2024 systematic review of intradermal botulinum toxin included ten studies involving 153 participants and reported improvements in several measures of skin quality. The authors called for further high-quality research, and subsequent correspondence questioned aspects of the analysis.
A meta-analysis is a starting point for examining the evidence, rather than a reason to stop asking questions. Promising findings still need to be considered alongside study size, methods and relevance to the patient in front of us.
“Liquid microneedling” needs similar scrutiny. The name sounds like a variation of an established procedure, but products marketed this way may use microscopic marine sponge-derived spicules rather than conventional needles.
A 2026 study involving 21 healthy women examined one microneedle cream over eight weeks, with participants receiving different levels of skincare instruction. It cannot validate every product or treatment marketed under the same label. A published paper only supports the claims its design and findings can actually sustain.
WHEN TEN TREATMENTS BECOMES THE SELLING POINT
I use combination treatments myself. Skin quality, pigmentation, vascular changes and volume loss can require different modalities, and combining them can make clinical sense.
What I find difficult is the idea that the number of treatments measures how advanced the plan is.
If somebody tells me they’ve had ten treatments in one day, my first thought isn’t “wow”. I want to know what they were, why each was indicated, how they might interact and whether there was any benefit to doing everything that day rather than staging treatment.
There’s also the question of what happens when the result isn’t what you expected.
If you’ve used an energy-based device, injected something, disrupted the skin barrier and applied active topical products, then the patient develops an unexpected reaction, establishing the cause may become considerably harder.
That can affect complication management, adverse event reporting and decisions about treating the patient again. Several simultaneous interventions introduce more variables, potentially making it harder to establish what went wrong. It matters for consent too. Is there evidence for the particular combination and sequence, or have individually plausible treatments simply been put together and assumed to be better? Has the patient been told about relevant uncertainty?
The more complicated the plan becomes, the more clinical reasoning it requires. I should be able to justify every treatment and explain why they needed to happen together. Otherwise, I’m not sure stacking is a treatment strategy at all.
Aesthetics isn’t a race where whoever adopts the most treatments first wins.
GOVERNANCE ISN’T THE BORING BIT
This is where the conversation becomes one about governance, and that doesn’t belong to one profession.
As a registered nurse and independent prescriber, I’m accountable to the NMC Code. It requires me to put people first, practise effectively, preserve safety and uphold professional standards. Other regulated healthcare professionals have their own professional obligations.
Being accountable means being able to explain what you’ve done, why you’ve done it and why it was appropriate for that patient.
Completing a course doesn’t automatically establish competence. Training matters, but so do knowledge, experience, judgement, understanding your limitations and knowing when not to treat. Being technically able to perform something isn’t the same as deciding whether you should.
Consent isn’t simply getting somebody to sign a form. If the evidence is emerging, the patient needs to understand that. If I’m combining treatments, they need to understand why, alongside realistic benefits, material risks and reasonable alternatives. Those alternatives may include staging treatment, doing less or doing nothing.
That last option sometimes seems to have disappeared from aesthetic medicine.
There’s an obvious commercial tension because aesthetics is both healthcare and business. Packages sell, and impressive treatment stacks make excellent content. Recognising that influence, and ensuring it doesn’t determine clinical decisions, is part of professional responsibility.
My expert witness work makes me look at this slightly differently too. After an adverse outcome, nobody is particularly interested in how fashionable the treatment was. They’re looking at the reasoning behind it.
Why was it chosen? Was the patient suitable? Were alternatives and material risks discussed? Were the records adequate, and was there a clear plan for managing complications?
Where treatments were combined, I’d also want to understand the sequencing, potential interactions and whether staging could have achieved the same outcome with less uncertainty.
“Because that’s the package” isn’t a clinical rationale.
WE HAVE OUR OWN PROBLEMS
None of this justifies looking at Korean practice from a position of assumed superiority. These questions apply wherever treatments are delivered, and social media offers only a selective picture of clinical practice.
The UK has its own problems around training, prescribing, competence and accountability. Professional registration provides an additional layer of oversight, but sound assessment, consent, records and complication planning should be expected of everyone providing aesthetic procedures.
Voluntary competency frameworks, including the JCCP’s, can help define expectations, but they don’t replace statutory regulation.
For me, governance should ask more than whether we’re legally or technically allowed to perform something. “Should I do this to this patient, today, alongside everything else I’m planning?” is the more useful question.
We should also be interested in the expectations behind the beautiful images. Beauty ideals have social and commercial influences, in South Korea as elsewhere. Admiring an aesthetic doesn’t mean accepting every pressure that accompanies it, or teaching patients that normal skin texture needs correcting.
ARE THEY REALLY TEN YEARS AHEAD?
I’m still not convinced “ahead” is the right word.
There’s plenty to learn from South Korea’s emphasis on skin quality and maintenance, and its appetite for technology and combination approaches. What I don’t think we need to do is follow every trend at the same speed.
We can be interested in a treatment performed in Seoul and still question its evidence. We can learn from combination approaches without making ten treatments in a day an aspiration.
Aesthetics isn’t a race where whoever adopts the most treatments first wins. Being able to explain a decision, support it with evidence, obtain informed consent and manage the consequences matters considerably more.
The question I keep returning to is simple: if this treatment didn’t have a catchy name, wasn’t all over social media and the patient hadn’t already decided they wanted it, would I still recommend it?
If the answer is yes, brilliant. Then I need to understand the evidence and use it appropriately. If it’s no, perhaps we need to ask who the treatment is actually for.
Because when everything goes beautifully, nobody is particularly interested in your governance. When it doesn’t, it’s the first thing everyone wants to see.
Scan for references:
JEN VITTANUOVA
Jen Vittanuova is a Registered Nurse Prescriber, aesthetic practitioner and expert witness with more than 25 years’ experience across nursing, cosmetic surgery and aesthetic medicine. Her clinical background includes maxillofacial and ENT head and neck surgery, breast and bowel surgery, wound care and advanced nursing practice, before establishing her own medical aesthetics practice.